Attached files

file filename
8-K - CURRENT REPORT ON FORM 8-K - Simulations Plus, Inc.simulations_8k.htm
EX-99.2 - PRESENTATION - Simulations Plus, Inc.simulations_8k-ex9902.htm

Exhibit 99.1

 

Simulations Plus

Integrating Science and Software

 

For Further Information:

Simulations Plus, Inc.

42505 10th Street West

Lancaster, CA 93534-7059

 

CONTACT:

Simulations Plus Investor Relations Hayden IR
Ms. Renée Bouché Mr. Cameron Donahue
661-723-7723 651-653-1854
renee@simulations-plus.com cameron@haydenir.com

 

For Immediate Release:

April 10, 2013

 

Simulations Plus Reports Second Quarter and First Six Months FY2013 Financial Results

 

Second quarter net sales increase 11.8%; net income up 26.5%

 

LANCASTER, CA, April 10, 2013 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2013 ended February 28, 2013 (2QFY13).

 

2QFY13 highlights compared with 2QFY12:

·Net sales increased 11.8% to new record for any quarter of $3.118 million from $2.789 million
·This was the Company’s 22nd consecutive profitable quarter, and the 44th of the last 46 quarters
·Gross profit increased 9.5% to $2.619 million from $2.393 million
·SG&A decreased 10.6% to $0.855 million from $0.956 million
oAs a percent of revenues, SG&A decreased to 27.4% from 34.3%
·R&D expense decreased 6.4% to $248,000 from $265,000
·Income before taxes from continuing operations increased 24.8% to $1.572 million from $1.260 million
·Provision for income taxes increased 21.3% to $0.511 million from $0.421 million
·Net income from continuing operations increased 26.5% to $1.062 million from $0.839 million
·Diluted earnings per share increased to $0.06 from $0.05 in 2QFY12
·Cash at the end of the second fiscal quarter was $9.75 million after dividend distributions
oApproximately $796,000 was distributed in November 2012
oApproximately $2,243,000 was distributed in December 2012
oCash as of April 5 was $10.4 million
·Shareholders’ equity at the end of the quarter was $13.921 million
oThis is a decrease of $1.505 million from the end of 2QFY12
oThis decrease was after dividend distributions of approximately $5.4 million during calendar 2012

For the first six months of fiscal year 2013 (6moFY13) compared to the first six months of FY2012 (6moFY12):

·Net sales increased 7.4% to a new midyear record $5.408 million from $5.037 million
·Gross profit increased 5.5% to $4.523 million from $4.288 million
·SG&A increased 7.8% to $1.786 million from $1.656 million
·As a percent of revenues, SG&A increased to 33.0% from 32.9%
·R&D expenditures decreased 17.2% to $428,000 from $517,000
1
 

 

oCompletion of the Company's malaria NCE project reduced R&D expenditures in the current year
·Income before taxes increased 6.2% to $2.468 million from $2.323 million
·Provision for income taxes increased 12.3% to $0.819 million from $0.729 million
·Net income from continuing operations increased 3.4% to $1.649 million from $1.594 million
·For 6moFY13, earnings per share from continuing operations was the same at $0.10 per share.
·Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, net income for 6moFY12 was $1.810 million
·Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, total diluted earnings per share for 6moFY12 was $0.11

 

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “We continued to exhibit the strong leverage in our business model as each dollar of incremental revenues added approximately $0.80 to operating profit. Record revenue up nearly 12% for the quarter delivered a 26.5% improvement in net income despite an increase in tax rates. After distributing cash dividends of over $5 million to our shareholders during calendar 2012, our cash position remains strong, and we continue to have no debt.”

 

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The second quarter continues our trend of new quarterly records each fiscal quarter, and this quarter is also a record for any quarter. We added 18 new customers, had 93% renewals, and increased our collaboration funding by over $111,000, while consulting revenues decreased by 27%. Results from two recent GastroPlus™ simulation contract studies were submitted to U.S. and European regulatory agencies in support of our customers, making a total of four such submittals in recent months. The acceptance of simulation results in support of regulatory applications has been increasing and we believe is a leading indicator for increased use of simulation and modeling software in the pharmaceutical industry to reduce the time and cost of unnecessary clinical trials.”

 

The Company has announced an investor conference call that will be webcast live at 1:30 PDT/4:30 PM EDT today, Wednesday, April 10, 2013, which may be accessed by registering here. Upon registering, you will receive a confirmation e-mail with a unique link and instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (646) 307-1720, and enter access code 951-402-096.

 

About Simulations Plus, Inc.

 

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

 

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

 

--Tables follow --

 

 

2
 

 

SIMULATIONS PLUS, INC. CONDENSED BALANCE SHEETS

at February 28, 2013 (Unaudited) and August 31, 2012 (Audited)

 

 

 

ASSETS
   February 28,   August 31, 
   2013   2012 
Current assets          
Cash and cash equivalents  $9,754,861   $12,701,075 
Income tax refund receivable   2,650    153,896 
Accounts receivable, net of allowance for doubtful accounts of $0   2,535,816    1,451,864 
Contracts receivable   86,995    18,893 
Prepaid expenses and other current assets   168,351    150,856 
Deferred income taxes   210,456    193,712 
Total current assets   12,759,129    14,670,296 
Long-term assets          
Capitalized computer software development costs,          
net of accumulated amortization of $5,443,703 and $5,084,691   2,702,535    2,479,468 
Property and equipment, net   94,091    107,410 
Intellectual property, net of accumulated amortization of $7,500 and $3,750   67,500    71,250 
Other assets   18,445    18,445 
Total assets  $15,641,700   $17,346,869 
           
           
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities          
Accounts payable  $254,737   $177,509 
Accrued payroll and other expenses   308,592    312,912 
Accrued bonuses to officer   30,000    60,000 
Accrued income taxes   27,859    733,233 
Deferred revenue   222,735    131,782 
Total current liabilities   843,923    1,415,436 
           
Long-term liabilities          
Deferred income taxes   876,968    788,857 
Total liabilities   1,720,891    2,204,293 
           
Commitments and contingencies          
           
Shareholders' equity          
Preferred stock, $0.001 par value          
10,000,000 shares authorized          
no shares issued and outstanding        
Common stock, $0.001 par value          
50,000,000 shares authorized          
16,021,309 and 15,923,019 shares issued and outstanding   4,493    4,399 
Additional paid-in capital   4,797,317    4,628,366 
Retained earnings   9,118,999    10,509,811 
           
Total shareholders' equity   13,920,809    15,142,576 
           
Total liabilities and shareholders' equity  $15,641,700   $17,346,869 

 

3
 

 

SIMULATIONS PLUS, INC. CONDENSED STATEMENTS OF OPERATIONS

For the three and six months ended February 28 and 29,

(Unaudited)

 

  Three months ended   Six months ended 
   2013   2012   2013   2012 
Net sales  $3,118,121   $2,789,226   $5,408,215   $5,037,182 
Cost of sales   498,778    396,566    885,648    748,936 
Gross profit   2,619,343    2,392,660    4,522,567    4,288,246 
Operating expenses                    
Selling, general, and administrative   854,983    956,325    1,786,043    1,656,438 
Research and development   247,522    264,581    427,857    516,516 
Total operating expenses   1,102,505    1,220,906    2,213,900    2,172,954 
Income from operations   1,516,838    1,171,754    2,308,667    2,115,292 
Other income (expense)                    
Interest income   17,074    25,083    30,802    46,956 
Interest expense               (3)
Miscellaneous income   15,390    22,656    30,794    22,656 
Gain on currency exchange   22,988    40,502    97,642    138,888 
Gain (loss) from sale of assets       (433)       (433)
Total other income (expense)   55,452    87,808    159,238    208,064 
Income from continuing operations before                    
provision for income taxes   1,572,290    1,259,562    2,467,905    2,323,356 
Provision for income taxes   (510,715)   (420,985)   (819,344)   (729,680)
Income from continuing operations   1,061,575    838,577    1,648,561    1,593,676 
Discontinued operations:                    
Gain (loss) from discontinued operations, net of tax               (249,898)
Gain on sale of Words+, net of tax               465,820 
Results of discontinued operations               215,922 
Net Income  $1,061,575   $838,577   $1,648,561   $1,809,598 
Basic earnings per share:                    
Continuing operations  $0.07   $0.05   $0.10   $0.10 
Discontinued operations               0.01 
Net basic earning per share  $0.07   $0.05   $0.10   $0.11 
Diluted earnings per share                    
Continuing operations  $0.06   $0.05   $0.10   $0.10 
Discontinued operations               0.01 
Net basic earning per share  $0.06   $0.05   $0.10   $0.11 
Weighted-average common shares outstanding                    
Basic   16,004,397    15,635,898    15,965,890    15,604,420 
Diluted   16,336,353    15,995,226    16,305,235    15,957,657 

 

 

4